{
    "xml": "<topic id=\"PHP1586\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/urokinase\" basename=\"urokinase\" title=\"UROKINASE\">\n<title>UROKINASE</title>\n<body>\n<data name=\"vtmid\">319826005</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_431464079\" title=\"Tissue plasminogen activators\">Tissue plasminogen activators</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34567\" title=\"FIBRINOLYTICS\" namespace=\"/drug-classes/fibrinolytics\">FIBRINOLYTICS</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">   </data>\n</data>\n</body>\n<topic id=\"PHP50943\" outputclass=\"indicationsAndDose\" rev=\"1.20\" parent=\"/drugs/urokinase\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Deep-vein thrombosis (thromboembolic occlusive vascular disease)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 4400&#8239;units/kg, to be given over 10&#8211;20 minutes, followed by 100&#8239;000&#8239;units/hour for 2&#8211;3 days.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Pulmonary embolism (thromboembolic occlusive vascular disease)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 4400&#8239;units/kg, to be given over 10&#8211;20 minutes, followed by 4400&#8239;units/kg/hour for 12 hours.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Occlusive peripheral arterial disease (thromboembolic occlusive vascular disease)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intra-arterial infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>(consult product literature).</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Occluded central venous catheters</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Inject directly into occluded catheter, to be dissolved in sodium chloride 0.9% to a concentration of 5000&#8239;units/mL; use a volume sufficient to fill the catheter lumen; leave for 20&#8211;60 minutes then aspirate the lysate; repeat if necessary.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Occluded arteriovenous haemodialysis shunts</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion or by intra-arterial infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>(consult product literature).</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP51033\" outputclass=\"breastFeeding\" parent=\"/drugs/urokinase\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP50975\" outputclass=\"hepaticImpairment\" parent=\"/drugs/urokinase\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Dose reduction may be required.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP50900\" outputclass=\"renalImpairment\" parent=\"/drugs/urokinase\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Dose reduction may be required.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP51070\" outputclass=\"directionsForAdministration\" rev=\"1.16\" parent=\"/drugs/urokinase\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use</p>\n<p>For <i>intravenous infusion</i> (<i>Syner-KINASE</i>\n<tm tmtype=\"reg\"/>), give continuously or intermittently in Sodium chloride 0.9%.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP1586-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/urokinase\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77015\" title=\"Powder for solution for injection\" namespace=\"/drugs/urokinase/powder-for-solution-for-injection\">Powder for solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78101\" namespace=\"/treatment-summaries/fibrinolytic-drugs\" title=\"Fibrinolytic drugs\" count=\"2\" rel=\"backlink\">Fibrinolytic drugs</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34567\" namespace=\"/drug-classes/fibrinolytics\" title=\"FIBRINOLYTICS\" count=\"1\" rel=\"link\">FIBRINOLYTICS</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77015\" namespace=\"/drugs/urokinase/powder-for-solution-for-injection\" title=\"Powder for solution for injection\" count=\"1\" rel=\"link\">Powder for solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP1586",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/urokinase",
    "basename": "urokinase",
    "title": "UROKINASE",
    "vtmid": "319826005",
    "drugClassification": [
        "Tissue plasminogen activators"
    ],
    "inheritsFromClass": [
        "FIBRINOLYTICS"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Deep-vein thrombosis (thromboembolic occlusive vascular disease)",
                        "html": "Deep-vein thrombosis (thromboembolic occlusive vascular disease)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "Initially 4400 units/kg, to be given over 10&#8211;20 minutes, followed by 100 000 units/hour for 2&#8211;3 days.",
                        "html": "<p>Initially 4400&#8239;units/kg, to be given over 10&#8211;20 minutes, followed by 100&#8239;000&#8239;units/hour for 2&#8211;3 days.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Pulmonary embolism (thromboembolic occlusive vascular disease)",
                        "html": "Pulmonary embolism (thromboembolic occlusive vascular disease)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "Initially 4400 units/kg, to be given over 10&#8211;20 minutes, followed by 4400 units/kg/hour for 12 hours.",
                        "html": "<p>Initially 4400&#8239;units/kg, to be given over 10&#8211;20 minutes, followed by 4400&#8239;units/kg/hour for 12 hours.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Occlusive peripheral arterial disease (thromboembolic occlusive vascular disease)",
                        "html": "Occlusive peripheral arterial disease (thromboembolic occlusive vascular disease)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intra-arterial infusion"
                    ],
                    "textContent": "By intra-arterial infusion",
                    "html": "By intra-arterial infusion"
                },
                "adult": [
                    {
                        "textContent": "(consult product literature).",
                        "html": "<p>(consult product literature).</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Occluded central venous catheters",
                        "html": "Occluded central venous catheters"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous injection"
                    ],
                    "textContent": "By intravenous injection",
                    "html": "By intravenous injection"
                },
                "adult": [
                    {
                        "textContent": "Inject directly into occluded catheter, to be dissolved in sodium chloride 0.9% to a concentration of 5000 units/mL; use a volume sufficient to fill the catheter lumen; leave for 20&#8211;60 minutes then aspirate the lysate; repeat if necessary.",
                        "html": "<p>Inject directly into occluded catheter, to be dissolved in sodium chloride 0.9% to a concentration of 5000&#8239;units/mL; use a volume sufficient to fill the catheter lumen; leave for 20&#8211;60 minutes then aspirate the lysate; repeat if necessary.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Occluded arteriovenous haemodialysis shunts",
                        "html": "Occluded arteriovenous haemodialysis shunts"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion or intra-arterial infusion"
                    ],
                    "textContent": "By intravenous infusion or by intra-arterial infusion",
                    "html": "By intravenous infusion or by intra-arterial infusion"
                },
                "adult": [
                    {
                        "textContent": "(consult product literature).",
                        "html": "<p>(consult product literature).</p>"
                    }
                ]
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid&#8212;no information available.",
                "html": "<p>Manufacturer advises avoid&#8212;no information available.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Dose reduction may be required.",
                "html": "<p>Dose reduction may be required.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Dose reduction may be required.",
                "html": "<p>Dose reduction may be required.</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "With intravenous use",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "For intravenous infusion (Syner-KINASE ), give continuously or intermittently in Sodium chloride 0.9%.",
                "html": "<p>For <i>intravenous infusion</i> (<i>Syner-KINASE</i>\n<tm tmtype=\"reg\"/>), give continuously or intermittently in Sodium chloride 0.9%.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP77015",
                "label": "Powder for solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78101",
                "label": "Fibrinolytic drugs",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "drugClass": [
            {
                "id": "PHP34567",
                "label": "FIBRINOLYTICS",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP77015",
                "label": "Powder for solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}